In the long struggle to understand multiple sclerosis, a two-year Swedish study of 509 newly diagnosed patients offers a partial answer and a deeper question: more aggressive early treatment can quiet the inflammatory storms of the disease, but whether that quieting protects the body over time remains unknown. B-cell-depleting therapies reduced relapses and brain lesions more effectively than oral medications, yet after two years, patients across all treatment groups were equally disabled. Science has illuminated one corridor while leaving the larger room in shadow.
B-cell therapies show early promise in MS control, but disability outcomes remain unclear
Fewer attacks, fewer brain lesions—but no difference in disability.
Mark
So B-cell therapies cut relapse rates by 62 percent. That sounds like a big deal. Why isn't that translating to less disability?
Mimi
That's the central mystery of the study. The drugs are clearly doing something—fewer attacks, fewer brain lesions. But after two years, patients on these aggressive treatments had the same disability scores as patients on weaker drugs or no treatment at all.
Luke
Hold on. The study doesn't prove the drugs caused the lower relapse rates. The patients weren't randomly assigned. Doctors chose treatments based on how sick they thought each patient was.
Mimi
Right. So it's possible that patients on B-cell therapies were sicker to begin with, and the drugs just kept them from getting worse faster. We can't separate the drug effect from the selection effect.
Mark
But if the drugs are preventing attacks and brain damage, shouldn't that eventually show up as better disability outcomes?
Mimi
You'd think so. But two years might not be long enough. MS disability often accumulates slowly. The real test is whether these early advantages compound over five or ten years.
Luke
And we don't have that data yet. The study is a snapshot. The authors say they're planning longer follow-up, but that's future work.
Mark
So what should a newly diagnosed patient actually do with this information?
Mimi
The study suggests that B-cell therapies are good at controlling inflammation in the short term. Patients on them had the best adherence rates too—94 percent stayed on them. But there's no evidence yet that this translates to less disability down the road.
Luke
Which means the choice still depends on the individual patient, their disease pattern, and their tolerance for infusions versus pills. The study doesn't settle the question of which treatment is best.
Mark
It just shows that the question is still open.
Mimi
Exactly. And that's actually useful information for doctors and patients to have.
O Pulso
- B-cell-depleting infusions cut relapse rates to nearly zero — 0.04 per year versus 0.16 for oral drugs — suggesting these therapies can suppress MS inflammation far more aggressively than standard options.
- The study's most unsettling finding is the silence where a signal should be: despite fewer relapses and smaller brain lesions, disability scores were identical across all treatment groups after two years.
- Confounding the picture further, doctors were not randomly assigning treatments — sicker patients may have been steered toward stronger drugs, potentially masking the true benefit of those drugs.
- Adherence data offered a quiet endorsement: 94 percent of patients on B-cell infusions were still on them after two years, far outpacing oral and injectable alternatives.
- The study's lead author has signaled that longer follow-up is planned, betting that two years is simply too short a window to see whether controlling early inflammation prevents the slow accumulation of disability over a decade.
In the long struggle to understand multiple sclerosis, a two-year Swedish study of 509 newly diagnosed patients offers a partial answer and a deeper question: more aggressive early treatment can quiet the inflammatory storms of the disease, but whether that quieting protects the body over time remains unknown. B-cell-depleting therapies reduced relapses and brain lesions more effectively than oral medications, yet after two years, patients across all treatment groups were equally disabled. Science has illuminated one corridor while leaving the larger room in shadow.
A September 2026 study tracked 509 newly diagnosed multiple sclerosis patients for two years as they began their first disease-modifying therapies, comparing five treatment paths ranging from injectable drugs to B-cell-depleting infusions to no treatment at all. The goal was to understand whether the choice of first treatment shapes the early course of the disease.
The B-cell-depleting drugs — including rituximab and ocrelizumab — produced the clearest early advantage. Patients on these infusions relapsed at a rate of 0.04 per year, compared to 0.16 for those on oral medications, and brain imaging showed modestly lower lesion volumes in the same group. After adjusting for age, sex, and disease duration, B-cell therapies were associated with 62 percent fewer relapses than oral treatments — a meaningful difference in controlling the inflammatory attacks that define relapsing MS.
Yet the study's most striking result was what remained unchanged. After two years, disability scores were essentially identical across all treatment groups, and blood markers of nerve cell damage showed no differences either. The gap between what the drugs appeared to accomplish and what patients actually experienced in terms of physical function was left unexplained.
The study's non-randomized design adds complexity: doctors chose treatments based on individual circumstances, meaning patients with more aggressive disease may have been steered toward stronger therapies — potentially obscuring the drugs' true effects. One cleaner signal emerged in adherence: 94 percent of patients on B-cell infusions were still taking them after two years, compared to 72 percent on oral medications and 61 percent on injectables.
Lead author Fredrik Piehl of Karolinska Institutet acknowledged the puzzle openly, noting that two years may simply be too short to detect how early inflammation control shapes long-term disability. Extended follow-up of the same cohort is planned — a necessary next chapter in determining whether suppressing relapses and lesions in the first years of MS ultimately protects against the progressive loss of function that defines the disease's most difficult arc.
A study of 509 newly diagnosed multiple sclerosis patients published in September 2026 found that the choice of initial treatment matters—but only in ways that may not ultimately change how sick people become. Researchers tracked patients for two years after they started their first disease-modifying therapy, comparing five different treatment paths: injectable drugs, oral medications, high-efficacy treatments, B-cell-depleting infusions, or no treatment at all.
The B-cell-depleting therapies—drugs like rituximab and ocrelizumab that reduce a specific type of immune cell—produced the clearest early advantage. Patients on these infusions experienced relapses at a rate of 0.04 per year, compared to 0.16 per year for those taking oral medications. When researchers adjusted for age, sex, and disease duration, the difference widened: B-cell therapies cut relapse rates by 62 percent relative to oral treatments. Brain imaging showed similar patterns. Lesion volume—a measure of disease-related scarring in the brain—was lower in the B-cell therapy group than in the oral medication group, though the difference was modest. These findings suggest that more aggressive early treatment does suppress the inflammatory attacks that define relapsing MS.
Yet the study's most striking finding was what did not change. After two years, disability scores were essentially identical across all treatment groups. Patients on B-cell therapies were no less disabled than those on weaker oral drugs or no treatment at all. Researchers also found no differences in serum neurofilament light chain, a blood marker of nerve cell damage, across any of the groups. The gap between what the drugs appeared to accomplish—fewer attacks, fewer brain lesions—and what patients actually experienced in terms of physical function remained unexplained.
The study involved 509 people with an average age of 33, all newly diagnosed with relapsing or progressive MS and treatment-naive. About 17 percent started injectable platform therapies, 30 percent took oral medications, 16 percent received high-efficacy drugs, 20 percent received B-cell-depleting infusions, and 18 percent received no treatment. The distribution reflected real clinical practice: doctors were not randomly assigning patients to treatments but rather choosing based on individual circumstances, which means sicker or more aggressive cases may have been steered toward stronger drugs.
One practical measure favored the B-cell therapies: adherence. After two years, 94 percent of patients on B-cell treatments were still taking them, compared to 87 percent on high-efficacy drugs, 72 percent on oral medications, 61 percent on injectable drugs, and 63 percent of untreated patients. This suggests the infusions were tolerable and patients believed in them, even if the disability benefit remained unclear.
Fredrik Piehl, the study's lead author from Karolinska Institutet in Stockholm, acknowledged the puzzle. Fewer relapses and fewer brain lesions should theoretically translate to less disability, yet the two-year data showed no such connection. He noted that the study cannot prove one treatment causes better outcomes than another—it only shows associations—and that the non-random assignment of patients to treatments means confounding factors may be at work. Doctors may have chosen aggressive therapies for patients with more aggressive disease, masking the true effect of the drugs themselves.
The findings leave a critical question unresolved: whether the early advantages of B-cell therapies in controlling inflammation will eventually translate to better long-term disability outcomes. Two years may simply be too short to detect differences in how much physical function patients retain. Piehl indicated that extended follow-up of the same cohort is planned, which may reveal whether suppressing relapses and lesions in the first two years protects against disability accumulation over a decade or more. For now, doctors and patients face a familiar dilemma—evidence that some treatments work better at controlling disease activity, but no proof that this control prevents the progressive loss of function that defines MS.
Citações Notáveis
People with MS and their doctors have more treatment choices than ever before, but it is still hard to know which treatment to start with. Even so, B-cell-depleting therapies were linked to fewer relapses and fewer MRI changes. But after two years, we did not see clear differences in disability scores.— Fredrik Piehl, MD, PhD, Karolinska Institutet, Stockholm
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine